Syros Pharmaceuticals, Inc. financial data

Symbol
SYRS on Nasdaq
Industry
Pharmaceutical Preparations
Location
35 Cambridge Park Drive, Cambridge, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Former names
LS22, Inc. (to 8/22/2012)
Latest financial report
Q1 2024 - May 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 407 % -26.5%
Return On Equity -409 % -333%
Return On Assets -91.5 % -111%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 26.5 M shares +30.3%
Common Stock, Shares, Outstanding 26.7 M shares +31%
Entity Public Float 58.6 M USD +5.06%
Common Stock, Value, Issued 26 K USD +30%
Weighted Average Number of Shares Outstanding, Basic 39 M shares +40%
Weighted Average Number of Shares Outstanding, Diluted 39 M shares +40%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 9.94 M USD -33.2%
Research and Development Expense 104 M USD -9.94%
General and Administrative Expense 27.1 M USD -8.78%
Operating Income (Loss) -127 M USD +11%
Income Tax Expense (Benefit) 1 K USD -66.7%
Net Income (Loss) Attributable to Parent -144 M USD -54.9%
Earnings Per Share, Basic -5.06 USD/shares -16.3%
Earnings Per Share, Diluted -5.06 USD/shares -16.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 83.5 M USD -20.3%
Marketable Securities, Current 24.8 M USD -59.4%
Cash, Cash Equivalents, and Short-term Investments 108 M USD
Assets, Current 112 M USD -35.4%
Property, Plant and Equipment, Net 6.96 M USD -36.4%
Operating Lease, Right-of-Use Asset 11.9 M USD -8.42%
Other Assets, Noncurrent 1.55 M USD -66.6%
Assets 135 M USD -34.4%
Accounts Payable, Current 11.3 M USD +306%
Employee-related Liabilities, Current 2.49 M USD -17%
Liabilities, Current 37.3 M USD +58.4%
Operating Lease, Liability, Noncurrent 17.9 M USD -11.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 49 K USD
Retained Earnings (Accumulated Deficit) -727 M USD -24.8%
Stockholders' Equity Attributable to Parent 15.1 M USD -85.9%
Liabilities and Equity 135 M USD -34.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -31.1 M USD +15.7%
Net Cash Provided by (Used in) Financing Activities -265 K USD -400%
Net Cash Provided by (Used in) Investing Activities -24.6 M USD +4.3%
Common Stock, Shares Authorized 70 M shares 0%
Common Stock, Shares, Issued 26.7 M shares +31%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -56 M USD +10.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 85.6 M USD -20.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.21 M USD +14.8%
Deferred Tax Assets, Valuation Allowance 169 M USD +31.7%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 174 M USD +29.8%
Operating Lease, Liability 20.3 M USD -9.3%
Payments to Acquire Property, Plant, and Equipment 272 K USD -78.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -145 M USD -56.1%
Lessee, Operating Lease, Liability, to be Paid 26.7 M USD -13.3%
Property, Plant and Equipment, Gross 14.9 M USD -37.5%
Operating Lease, Liability, Current 2.41 M USD +15.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.41 M USD +2.92%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.29 M USD +2.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 6.38 M USD -23.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 4.54 M USD +2.92%
Deferred Tax Assets, Operating Loss Carryforwards 95.3 M USD +16.2%
Preferred Stock, Shares Issued 0 shares
Current Income Tax Expense (Benefit) 1 K USD -66.7%
Preferred Stock, Shares Authorized 10 M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 4.54 M USD +2.92%
Operating Lease, Payments 1.04 M USD +2.98%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 334 K USD -47.6%
Deferred Tax Assets, Net of Valuation Allowance 4.72 M USD -14.2%
Share-based Payment Arrangement, Expense 9.89 M USD -11.6%
Interest Expense 5.22 M USD +19.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%